As Human Genome Sciences prepares to rake in its anticipated billions from sales of its newly approved lupus drug, the Rockville biotech's smaller brethren strive to duplicate that success.
What they need to get there, more than anything, is money — for research and development, salaries, equipment, licensing deals and rent.
But in a post-Great Recession environment in which investors still remain wary of companies that have yet to prove themselves with a solid deal or technology milestone, many private biotechs find themselves turning to a variety of other capital sources, from government grants and contracts to licensing deals and debt.
To read the full, original article click on this link: With VC scarce, where's the money?
Author: Lindsey Robbins
